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OBJECTIVES: Patients with human papillomavirus (HPV)–positive tonsillar squamous cell carcinoma (TSCC) and base of
tongue squamous cell carcinoma (BOTSCC) have a better clinical outcome than thosewith corresponding HPV-negative
tumors.Moreover, there is a strong positive correlation between absent/lowas opposed to strongHLAclass I expression
and favorable clinical outcome for HPV-positive tumors, while the reverse applies to HPV-negative tumors. The
expression of the antigen processing machinery (APM) components TAP1, TAP2, LMP2, and LMP7 in these tumors in
relation to HPV status, HLA class I expression, each other, and clinical outcome was therefore investigated.
MATERIAL AND METHODS: Formalin-fixed paraffin-embedded TSCC and BOTSCC, derived from 151 patients and
previously analyzed for HPV DNA, HLA class I, and LMP10 expressionwere stained by immunohistochemistry for TAP1,
TAP2, LMP2, and LMP7. RESULTS: Absent/low TAP2, LMP2, and LMP7 expression, similar to HLA class I and LMP10,
was common in TSCC and BOTSCC, irrespective of HPV status. Expression of TAP1 and TAP2 was correlated, as was
LMP2 to LMP7. LMP2 and LMP7expressionwas also associated toHLA class I expression.Moreover, absence of LMP7
was linked to increased disease-free survival in both HPV-positive and HPV-negative cases. CONCLUSION: Reduced
expression of TAP2, LMP2, and LMP7 was frequent in TSCC and BOTSCC and their expression as well as that of TAP1
was often interrelated. Furthermore, low LMP7 expression correlated to better clinical outcome and may, together with
HPV status, potentially be used for prediction of treatment response.
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Recently, an increased incidence of oropharyngeal squamous cell
carcinoma (OPSCC) was noted throughout the Western world,
in particular for tonsillar squamous cell carcinoma (TSCC) and base
of tongue squamous cell carcinoma (BOTSCC), the most common
OPSCC types [1–7]. This increase was attributed to an increased
prevalence of human papillomavirus (HPV) in OPSCC, especially in
TSCC and BOTSCC, rather than smoking and alcohol, the two
other main risk factors for these tumors [8]. Currently, a substantial
part of TSCC and BOTSCC are HPV positive and have a better
survival than the corresponding negative tumors (with roughly 80%
to 40% 5-year survival) [2,5,7,9–12]. The reason for the increased
survival for patients with HPV-positive tumors has not been
established. However, a positive correlation between the number of
tumor-infiltrating CD8+ lymphocytes and clinical outcome has beendemonstrated, indicating an influence of the immune system [13,14].
It was therefore surprising that in HPV-positive tumors, absent or low











n Percentage n Percentage n Percentage
Age (years)
Mean 61 63 62 .227
Median 61 62 61
Diagnosis
TSCC 48 47.5% 30 60.0% 78 51.7% .149
BOTSCC 53 52.5% 20 40.0% 73 48.3%
Sex
Male 71 70.3% 39 78.0% 110 72.8% .317
Female 30 29.7% 11 22.0% 41 27.2%
Tumor size
T1 26 25.7% 10 20.0% 36 23.8% .024
T2 38 37.6% 9 18.0% 47 31.1%
T3 18 17.8% 16 32.0% 34 22.5%
T4 19 18.8% 15 30.0% 34 22.5%
Nodal disease
N0 15 14.9% 23 46.0% 38 25.2% b .001
N1 28 27.7% 4 8.0% 32 21.2%
N2a 15 14.9% 3 6.0% 18 11.9%
N2b 29 28.7% 10 20.0% 39 25.8%
N2c 11 10.9% 6 12.0% 17 11.3%
N3 3 3.0% 4 8.0% 7 4.6%
NX 0 0.0% 0 0.0% 0 0.0%
Distant metastasis
M0 97 96.0% 50 100.0% 147 97.4% .362
M1 3 3.0% 0 0.0% 3 2.0%
MX 1 1.0% 0 0.0% 1 0.7%
Stage
I 1 1.0% 8 16.0% 9 6.0% .003
II 6 5.9% 4 8.0% 10 6.6%
III 29 28.7% 11 22.0% 40 26.5%
IV 65 64.4% 27 54.0% 92 60.9%
Treatment
Curative 98 97.0% 46 92.0% 144 95.4% .167
Palliative 3 3.0% 4 8.0% 7 4.6%
n denotes number of patients/tumors.
P value for comparison of HPV-positive versus HPV-negative tumors/patients.
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favorable clinical outcome, while the opposite applied for HPV-
negative TSCC and BOTSCC, where 31% of the tumors had absent
or low expression [15,16]. Low or absent HLA class I expression,
frequently found both in head and neck squamous cell carcinoma
(HNSCC) and in other tumors, should abrogate an immune response
and is, in general, correlated to a poor clinical outcome [17–22]. In
this context, further analysis on the expression of other components
of the antigen processing machinery (APM), such as LMP2, LMP7,
LMP10, TAP1, and TAP2, affecting the formation of peptide
presenting HLA-b2m complexes, seemed of importance [23,24].
LMP2, LMP7, and LMP10 are subunits of the immunoproteasome,
responsible for the processing of proteins to peptides, while TAP1 and
TAP2 transport peptides from the cytoplasm to the endoplasmic
reticulum [25,26]. This was emphasized by our recent finding that a
low nuclear LMP10 expression was correlated to a favorable clinical
outcome in HPV-positive tumors, whereas for HPV-negative tumors
a moderate/high cytoplasmic LMP10 expression correlated to a good
clinical outcome [27]. Thus, the HPV status of the tumor is critical
for the evaluation of both HLA class I and LMP10 in relation to
clinical outcome.
In contrast to the many reports on HLA class I expression and
cancer, including HNSCC, fewer studies have been performed on
other APM components besides HLA. In cervical carcinoma, where
virtually all tumors are HPV positive, defects in APM components are
commonly found [26]. Furthermore, expression of APM components
LMP2, LMP7, TAP1, TAP2, and HLA class I correlated to clinical
outcome in HNSCC [21]. However, the relation in expression
between different APM components, besides their association with
prognosis, is rarely evaluated nor, to our knowledge, have HPV status
been taken into account in previous studies of APM components
and HNSCC.
In this study, we have analyzed the expression of APM components
TAP1, TAP2, LMP2, and LMP7, their potential interrelationships,
as well as possible association to HLA class I and LMP10 expression,
using previously obtained data on HLA class I and LMP10 expression
in TSCC and BOTSCC [15,16,27]. Furthermore, we specifically
investigated if HLA class I expression was correlated to that of any
other APM component and whether the expression of any additional
APM component was correlated to clinical outcome.
Materials and Methods
Patients and Tumor Biopsies
Two patient cohorts, one diagnosed with TSCC and one with
BOTSCC, with a total of 151 patients, all treated at Karolinska
University Hospital (Stockholm, Sweden) were included in the study
(for details, see Table 1). The first sample set consisted of 78 TSCC
samples (ICD-10 C09.0-9), derived from patients diagnosed from
2000 to 2006, treated with the intention to cure and with available
pretreatment paraffin-embedded tumor biopsies. This set included 48
HPV DNA–positive and 30 HPV-negative TSCC samples, derived
from a set of 83 TSCC samples included in the analysis of HLA class I
and tumor-infiltrating CD8+ and FoxP3+ but with five tumors
excluded due to lack of material (for details, see [13,15]). The second
set consisted of all 73 BOTSCC samples (ICD-10, C01.9), 53 HPV
DNA positive and 20 HPV negative, from patients diagnosed from
2000 to 2007, with available pretreatment biopsies, and 66 of these
were treated with curative intent, while the rest received palliativetreatment. Data on HPV DNA status and p16INK4a (p16) status
(by immunohistochemistry) were obtained from previous studies
[1,6,11,28]. As described in these studies, detection of HPV DNA
was performed by polymerase chain reaction using the general primer
pairs GP5+/6+ and CPI/IIG, HPV16-specific primers, and in some
cases, sequencing. HPV DNA–positive and p16-negative samples
were excluded from the sample sets to minimize the risk of including
samples with inactive HPV DNA. Thus, HPV status in the presented
study was defined as positive for tumors with both presence of HPV
DNA and expression of p16 or negative for tumors lacking HPV
DNA, regardless of the expression of p16. Of the 101 HPV DNA–
positive tumors, 91 were HPV16, 6 HPV33, 2 HPV35, and 1 each
with HPV56 and HPV58. Treatment of the 144 patients treated with
intention to cure consisted of accelerated radiotherapy (RT)
(1.1 + 2.0 Gy/day for 4.5 weeks, total dose: 68 Gy) or conventional
RT (2.0 Gy/day, for 6.5-7 weeks, total dose: 68 Gy) in 111 cases
and induction chemotherapy followed by concomitant RT in
33 cases. After therapy, patients were followed up by clinical
examination every 3 months during the first 2 years and every
6 months starting from the third year. The study was approved by the
Regional Ethical Committee at Karolinska Institutet (Stockholm, Sweden)
according to ethical permissions 2005/431-31/4, 2005/1330-32, and
2009/1278-31/4.
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For staining the following antibodies and dilutions were used: for
TAP1, rabbit polyclonal H-300 (1:100); for TAP2, rabbit polyclonal
H210 (1:100), both from Santa Cruz Biotechnology, Inc (Dallas,
TX, USA); for LMP2, rabbit polyclonal antibody ab3328 (1:1000);
for LMP7, ab3329 (1:500), both from Abcam (Cambridge, United
Kingdom). As secondary antibodies, BA-1000 anti-rabbit (1:200) and
BA-2000 anti-mouse (1:200) both from Vector Laboratories
(Burlingame, CA, USA) were used. The tumors included in the present
study were formerly evaluated for LMP10 with ab C-2 (Santa Cruz
Biotechnology, Inc) [27], and for HLA class I with mouse monoclonal
antibodies HCA-2 and HC-10 [15,16]. Data from these studies have
been included in the present study for comparison to other APM
components.
Immunohistochemistry
Staining was performed essentially as described in Näsman et al.
[15]. Briefly, formalin-fixed paraffin-embedded tumor biopsy slides
(4 mm) were deparaffinized in xylene and rehydrated in ethanol
of decreasing concentrations. Heat-mediated antigen retrieval took
place in citrate buffer (pH 6.0). Horse serum (1.5%) diluted in
phosphate-buffered saline was used for blocking of unspecific sites,
followed by overnight incubation (+8°C) with primary antibodies
in a moist chamber. Secondary antibodies were applied and the
Avidin-Biotin-Peroxidase Complex (ABC) Kit (Vectastain; Vector
Laboratories, Burlingame, CA, USA) was used for antigen detection.
Chromogen-39-diaminobenzidine (DAB) was used for visualization,
and hematoxylin was used for counterstaining. Staining of tissue
sections with secondary antibody alone served as negative controls.
Evaluation of Immunostaining
Staining of tumor samples, including negative and positive
controls, was evaluated by two researchers blinded for all other
information about the samples. For cases where the evaluation
differed, a consensus was reached. The fraction of malignant cells
stained for each of the markers was evaluated separately for
cytoplasmic and nuclear compartments. The percentage of stained
tumor cells was scored as follows: 0—0%, 1—1% to 25%, 2—26%
to 50%, 3—51% to 75%, or 4—76% to 100%. Staining intensity
was scored separately as absent, weak, moderate, and strong. All
examined APM components showed strong expression in stromal
tissue as well as in tumor-infiltrating immune cells, thus serving as
internal positive controls. In cases where tumor cell staining was
uneven, the intensity of the majority of the cells was used in the
analysis. Cases were the staining was not possible to evaluate adequately
were excluded.
Statistical Evaluation
Student’s t test was used for comparison of mean values, and Fisher
exact test was used for categorical data. Spearman rank correlation test
was used for the comparison of the expression of the different APM
components together as well as with the expression of HLA class I
(HCA-2 and HC-10 antibodies). Clinical outcome and survival of
patients were measured in years from the date of diagnosis until the
occurrence of an event or until 3 years after diagnosis, where
patients were censored. Events were defined as death due to any cause
(overall survival, OS), death with TSCC or BOTSCC present
(disease-specific survival, DSS) or recurrence in disease [disease-free
survival (DFS)]. Patients who died without a documented TSCC orBOTSCC present were considered as a censored observation in DSS
and patients who died without a prior recurrence were censored at day
0 in DFS. The Kaplan-Meier estimator was used for the estimation of
DFS, DSS and OS, and differences in survival were tested using the
log-rank test. For the P values obtained and presented in Figure 2, all
three groups were compared. All analyses were performed using IBM
Corp SPSS Statistics version 21.0 except from Fischer exact test that
was performed in R statistical software version 2.15.3 [29].
Results
Patient and Tumor Characteristics
The main characteristics of the patients and their tumors are
presented in Table 1. As noted above, the study cohort consisted of 151
tumor samples, 78 TSCC and 73 BOTSCC samples. In total, 67% of
the tumors were HPV DNA positive, 48% and 52% for TSCC and
BOTSCC, respectively. As noted in the Material and Methods section,
noHPVDNA–positive and p16-negative samples were included in this
study. As has been stated elsewhere, HPV DNA–positive tumors were,
on average, associated with a higher nodal staging score [16].
Expression of APM Components in TSCC and BOTSCC
For each of the included APM components, TAP1, TAP2, LMP2, and
LMP7, between 127 and 147 of the 151 included TSCC and BOTSCC
sampleswere stained and evaluated for nuclear and cytoplasmic expression.
Representative staining patterns of both nuclear and cytoplasmic
expression of the different APM components are presented in Figure 1.
The expression of the APM components, evaluated by intensity of
cytoplasmic or nuclear staining, for TSCC and BOTSCC separately
and together, and according to HPV status (as defined in the Material
and Methods section), is shown in Tables 2 and 3, respectively. For
comparison, data on LMP10 expression in these tumors, derived from
the study by Tertipis et al. [27], are also included in both tables.
As presented in Table 2, cytoplasmic expression of TAP2, LMP2,
and LMP7 was absent or weak in a substantial fraction (33-59%) of
the tumors, while LMP10 was reduced in even more (87%) of the
tumors, whereas TAP1 only had a reduced expression in 9%.
Similarly, nuclear TAP1, TAP2, LMP2, LMP7, and LMP10
expression was absent or weak in 18% to 58% of the tumors, with
the least for TAP1 and the most for LMP2 (Table 3).
Expression of APM Components in Relation to Tumor Site
The expression of the APM components was generally similar in
TSCC and BOTSCC both with regard to cytoplasmic and nuclear
expression. However, there was a slightly lower cytoplasmic
expression of LMP7 and possibly LMP2, as well as lower nuclear
expression of LMP10 and a higher expression of TAP1 in TSCC as
compared to BOTSCC (Tables 2 and 3). The LMP10 data are from
Tertipis et al. [27], but there they were not presented per subsite.
Expression of APMComponents in Relation to TumorHPV Status
The expression of APM components was also evaluated in relation to
theHPV status of the tumors (Tables 2 and 3). There was no difference
in TAP1, TAP2, LMP2, and LMP7 expression in HPV-positive and
HPV-negative tumors, while, as presented in Tertipis et al., there was
a minor difference with regard to cytoplasmic LMP10 expression [27].
Correlations between the Different APM Components
To investigate whether there was any association in expression
















Figure 1. Examples of some of the expression patterns observed for APM components in TSCC and BOTSCC. (A–C) TAP1: (A) strong
nuclear and moderate cytoplasmic; (B) absent nuclear and strong cytoplasmic; (C) moderate nuclear and cytoplasmic. (D–F) TAP2:
(D) moderate nuclear and cytoplasmic; (E) absent nuclear and weak cytoplasmic; (F) weak nuclear and cytoplasmic. (G–I) LMP2: (G) strong
nuclear and cytoplasmic; (H) strong nuclear and weak cytoplasmic; (I) moderate nuclear and cytoplasmic; (J–L) LMP7: (J) moderate nuclear
and strong cytoplasmic; (K) moderate nuclear and weak cytoplasmic; (L) absent nuclear and cytoplasmic. Original magnification, x400.
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expression, as well as for intensity and fraction of positive cells,
and presented in cross-tables. The results of these calculations for
the intensity of the cytoplasmic and nuclear staining are presented
in Tables 4 and 5, respectively, while the results for the fraction of
positive cells are not presented. All calculations were performed
separately for HPV-positive and HPV-negative tumors. In this
evaluation, earlier data obtained for LMP10 [27] and for HLA class I
expression (evaluated by both HC-10 and HCA-2 antibodies)
[15,16] were included in the analysis. As presented in both Tables 4
and 5, several significant correlations were found.
There was a significant correlation in cytoplasmic intensity between
TAP1 and TAP2, and also between LMP2 and LMP7, irrespective of
HPV status (Table 4). Notably, for the fraction of cells positive in the
cytoplasm, both LMP2 and LMP7were significantly correlated toHLA
class I (HC-10) expression in HPV-positive tumors (data not shown).
In addition, several weaker and more inconsistent correlations werenoted. As expected, given the large overlap in their targets, there was a
strong correlation in the staining with the two HLA class I antibodies
HC-10 and HCA-2 (Table 4).
Nuclear intensity staining was also significantly correlated
between TAP1 and TAP2 as well as between LMP2 and LMP7,
irrespective of HPV status (Table 5). Furthermore, both LMP2
and LMP7 nuclear intensity staining was correlated to HLA class
I (HC-10) expression in HPV-positive tumors (Table 5).
Moreover, LMP7 expression was correlated to TAP2, irrespective
of HPV status, and to TAP1 in HPV-negative tumors (Table 5).
LMP10 was, in general, not correlated to any of the other examined
APM components.
Correlation of Expression of APM Components with
Clinical Outcome
DFS, disease-specific survival (DSS), and overall survival (OS) in



















Figure 2. Kaplan-Meier curves for DFS of patients with TSCC and BOTSCC treated with intention to cure stratified by the intensity of
nuclear staining for LMP2 for HPV-positive (A) and HPV-negative (B) cases and for LMP7 for HPV-positive (C) and HPV-negative (D) cases;
n denotes the number of patients in each group.
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curative intent, and separately for patients with HPV-positive and
HPV-negative tumors (Figure 2), since the former usually have a
better clinical outcome [7].Table 2. Intensity of Cytoplasmic Staining for APM Components in TSCC and BOTSCC in





P Value P Value †
TSCC BOTSCC Positive Negative
TAP1 Absent 0.0% 1.4% 1.0% 0.0% 0.7% .200 .785
Weak 5.2% 12.9% 10.2% 6.1% 8.8%
Moderate/
strong
94.8% 85.7% 88.8% 93.9% 90.5%
TAP2 Absent 0.0% 1.5% 1.0% 0.0% 0.7% .542 .386
Weak 35.9% 27.9% 36.1% 24.5% 32.2%
Moderate/
strong
64.1% 70.6% 62.9% 75.5% 67.1%
LMP2 Absent 14.1% 10.5% 13.1% 11.4% 12.5% .063 .724
Weak 54.9% 35.1% 46.4% 45.5% 46.1%
Moderate/
strong
31.0% 54.4% 40.5% 43.2% 41.4%
LMP7 Absent 8.7% 0.0% 3.5% 6.5% 4.5% .028 .559
Weak 44.9% 41.3% 44.2% 41.3% 43.2%
Moderate/
strong
46.4% 58.7% 52.3% 52.2% 52.3%
LMP10 Absent 29.5% 31.5% 22.8% 46.0% 30.5% .293 .014
Weak 52.6% 60.3% 60.4% 48.0% 56.3%
Moderate/
strong
17.9% 8.2% 16.8% 6.0% 13.2%
Fisher exact test on TSCC versus BOTSCC.
† Fisher exact test on HPV-positive versus HPV-negative tumors.Nuclear expression of LMP7 was significantly correlated to DFS, both
for HPV-positive and HPV-negative tumors (P = .023 and P = .049,
respectively; Figure 2). Absent nuclear expression of LMP7was correlated
to increased survival, whereas strong LMP7 nuclear expression wasTable 3. Intensity of Nuclear Staining for APM Components in TSCC and BOTSCC in Relation
to HPV Status




P Value P Value †
TSCC BOTSCC Positive Negative
TAP1 Absent 1.3% 10.0% 7.1% 2.0% 5.4% .049 .242
Weak 9.1% 15.7% 14.3% 8.2% 12.2%
Moderate/
strong
89.6% 74.3% 78.6% 89.8% 82.3%
TAP2 Absent 12.8% 20.6% 16.5% 16.3% 16.4% .248 .165
Weak 32.1% 26.5% 35.1% 18.4% 29.5%
Moderate/
strong
55.1% 52.9% 48.5% 65.3% 54.1%
LMP2 Absent 29.6% 21.1% 28.6% 20.5% 25.8% .589 .364
Weak 32.4% 31.6% 34.5% 27.3% 32.0%
Moderate/
strong
38.0% 47.4% 36.9% 52.3% 42.2%
LMP7 Absent 27.5% 23.8% 26.7% 23.9% 25.8% .507 .650
Weak 23.2% 30.2% 29.1% 21.7% 26.5%
Moderate/
strong
49.3% 46.0% 44.2% 54.3% 47.7%
LMP10 Absent 26.9% 6.8% 16.8% 18.0% 17.2% .006 .864
Weak 20.5% 26.0% 21.8% 26.0% 23.2%
Moderate/
strong
52.6% 67.1% 61.4% 56.0% 59.6%
Fisher exact test on TSCC versus BOTSCC.
† Fisher exact test on HPV-positive versus HPV-negative tumors.
Table 4. Spearman Rank Correlation of Cytoplasmic Expression of APM Components.
TAP1 TAP2 LMP2 LMP7 LMP10 HCA2 HC10
Rho
a 1.000 .384** .040 .137 .003 .054 .030
p-value
. .000 .721 .210 .980 .608 .772
Rho
.563** 1.000 .174 .308** .064 .129 .057
p-value
.000 . .113 .004 .532 .219 .587
Rho
-.008 .072 1.000 .724** .013 .132 .190
p-value
.957 .641 . .000 .907 .243 .092
Rho
.135 .136 .508** 1.000 -.115 .150 .164
p-value
.378 .374 .000 . .293 .179 .140
Rho
-.046 -.079 -.062 -.294* 1.000 -.128 -.136
p-value
.753 .589 .690 .048 . .210 .183
Rho
-.150 -.185 .149 -.125 .249 1.000 .846**
p-value
.324 .224 .351 .435 .100 . .000
Rho
-.229 -.277 .047 -.221 .175 .678** 1.000
p-value
.131 .066 .771 .166 .249 .000 .
aSpearman correlation  coefficient
* Correlation significance at the 0.05 level Positive correlation
















Table 5. Spearman Rank Correlation of Nuclear Expression of APM Components.
TAP1 TAP2 LMP2 LMP7 LMP10 HCA2 HC10
Rho
a 1.000 .456** .156 .168 -.090 -.009 .053
p-value
. .000 .159 .124 .380 .928 .609
Rho
.700** 1.000 .204 .304** .182 .081 .045
p-value
.000 . .062 .005 .074 .442 .672
Rho
.220 .449** 1.000 .721** .177 .188 .252*
p-value
.152 .002 . .000 .107 .095 .024
Rho
.446** .566** .753** 1.000 .117 .266* .273*
p-value
.002 .000 .000 . .285 .016 .013
Rho
.160 .133 -.133 .054 1.000 .008 .090
p-value
.273 .363 .391 .719 . .939 .382
Rho
-.278 -.345* -.039 -.127 .073 1.000 .846**
p-value
.065 .020 .808 .430 .636 . .000
Rho
-.271 -.341* -.043 -.180 .057 .678** 1.000
p-value
.072 .022 .791 .260 .710 .000 .
aSpearman correlation  coefficient
*Correlation significance at the 0.05 level Positive correlation
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LMP7 expression fell into a category between those with absent and those
with a moderate/strong expression in HPV-positive tumors, while in
HPV-negative tumors it was correlated to poor survival. In addition,
absence of LMP7 nuclear expression in HPV-negative tumors was also
significantly correlated to both increased OS and DSS (P = .016 and
P = .042, data not shown). LMP2 nuclear expression in relation to
DFS showed a very similar pattern to that of LMP7, although this result
was not statistically significant (Figure 2). Cytoplasmic expression of
LMP2 and LMP7 were, however, not associated to survival (data not
shown). Similarly, no significant correlation was found for TAP1 and
TAP2 in relation to clinical outcome (data not shown).
Discussion
In this study, the expression of TAP1, TAP2, LMP2, and LMP7 in
TSCC and BOTSCC was found, with the exception of TAP1, to be
frequently reduced, irrespective of HPV status. Possible correlations
between the above APM components and LMP10 and HLA class I
expression from previous data [15,16,27] were also analyzed. There
were significant correlations in the expression of TAP1 and TAP2, as
well as between LMP2 and LMP7, irrespective of tumor HPV status.
In addition, nuclear LMP2 and LMP7 expression was correlated to
HLA class I expression in HPV-positive tumors. Finally, of note,
absent/low LMP7 nuclear expression was correlated to better DFS in
patients with HPV-positive tumors.
Reduced expression of APM components in tumors is common
and is often shown for HLA class I antigens and regarded as a way to
evade the immune defence ([18,21,22,30–33]. We have also reported
that HLA class I expression is frequently absent or low in both HPV-
positive and HPV-negative TSCC and BOTSCC. Notably, in HPV-
positive tumors, this was correlated to a favorable clinical outcome,
while the reverse was true for HPV-negative cancer [15,16]. Reduced
expression of other APM components besides HLA class I has also
been demonstrated, e.g., in HNSCC, laryngeal squamous cell
carcinoma, cervical and urothelial cancers, and malignant melanoma
[21,22,26,30,31]. Thus, in HNSCC and cervical carcinoma, TAP1,
TAP2, LMP2, and LMP7 expression was frequently reduced,
although LMP7 reduction was not as pronounced in the latter
[21,26]. The frequencies of absent or reduced TAP1, TAP2, LMP2,and LMP7 expression in the HNSCC study by Meissner et al. were
also somewhat higher than those presented here, but in line with our
data, TAP1 was less frequently reduced than TAP2 [21].
In the current study, all APM components were evaluated for both
cytoplasmic and nuclear expression. It was noted that, for some tumors,
the expression of specific APM components was more pronounced in
the cytoplasm, while others were mainly present in the nucleus. The
cytoplasm is assumed to be the active compartment for these proteins,
but the significance of nuclear staining for peptide presentation byHLA
class I antigens especially in tumors as well as their effects on the
immune response has not been investigated thoroughly. Variations in
cytoplasmic and nuclear localization of APM components have been
observed previously. In one report, the thymus presented pronounced
LMP2 and LMP7 nuclear localization, while in liver cells their
distribution of LMP2 and LMP7 between the cytoplasm and nucleus
was more even [34]. In the present study, both strong cytoplasmic and
nuclear LMP2 and LMP7 staining of the stroma and tumor-
infiltrating lymphocytes were observed. Furthermore, notably, in
an earlier study, we have shown that low nuclear LMP10
expression was found to be significantly correlated to a favorable
clinical outcome, demonstrating the validity of evaluating nuclear
staining of APM components in relation to clinical outcome [27].
The correlation between the expression of different APM compo-
nents, e.g., between TAP1 and TAP2, between LMP2 and LMP7, and
between TAP2 and LMP7, was not unexpected. The genes for TAP1,
TAP2, LMP2, and LMP7 are all located within a narrow region of the
class II cluster of the major histocompatibility complex on chromosome
6 [35], with TAP1/LMP2 regulated by a bidirectional promoter, and
e.g., in Ad 12–transformed mouse cells, all four are downregulated,
indicating a common regulation [36,37]. In contrast, the expression of
LMP10 was not correlated to any of the other investigated APM
components, possibly due to its gene location on chromosome 16 [38].
However, despite LMP10 not being located in the vicinity of LMP2 and
LMP7, the expression of all three genes is regulated by interferon-γ [39].
To investigate whether the reduced HLA class I expression in
TSCC and BOTSCC was dependent or independent of the other
analyzed APM components, possible correlations were examined. For
HPV-positive tumors, both LMP2 and LMP7 expression were
correlated to HLA class I expression, and when HLA class I expression
16 Reduced Expression of TAP2, LMP2 and LMP7 in Oropharyngeal Cancer Tertipis et al. Translational Oncology Vol. 8, No. 1, 2014was reduced, expression of LMP2 and LMP7 was often also reduced.
This is in line with a study in felinemammary carcinoma by Favole et al.,
where the expression of LMP2 and LMP7were both correlated to that of
HLA class I [40]. Similarly, in a study on laryngeal squamous cell
carcinoma, a correlation between the expression of LMP2 andHLA class
I was noted [22].
Earlier studies have shown that the HLA class I heavy chain
promoter can be repressed by the HPV16 and 18 E7 proteins [41].
Besides, the bidirectional promoter of TAP1 and LMP2 is repressed
by HPV18 E7 but not by HPV16 E7 [41]. It is therefore conceivable
that other APM components can be repressed by E7. In this study, with
absolute dominance of HPV16, LMP2 reduction should consequently
not be dependent on E7 repression. Moreover, since no major
differences were observed between HPV-positive and HPV-negative
tumors in the decreased expression of TAP2, LMP2, LMP7, and
LMP10, the decline was likely not due to HPV. Several other different
mechanisms for down-regulation of the APM components have been
described, such as mutations, promoter methylation, and transcriptional
or post-transcriptional regulation [33].
Notably, low nuclear expression of LMP7 was significantly
correlated to longer DFS, both for HPV-positive and HPV-negative
tumors, and with OS and DSS only for HPV-negative tumors. LMP2
showed a similar tendency, although not statistically significant. This
finding is analogous to the earlier demonstration that low HLA class I
and low nuclear LMP10 expression both are positive factors in HPV-
positive TSCC and BOTSCC [15,16,27]. However, in the present
study, the absence of LMP7 expression was a positive factor for
survival also in patients with HPV-negative tumors and did
not parallel the worse survival for patients with HPV-negative low
HLA class I expressing TSCC or BOTSCC or low LMP7 expressing
HNSCC [15,21]. Correlations between APM component expression
and clinical outcome are generally interpreted to be associated to
effects on the ability of the immune system to elicit an immune
response to the tumor. However, LMP2, LMP7, and LMP10 also
play a role with regard to cell survival and proliferation and protect
cells against oxidative damage [25]. A high nuclear expression of
LMP2 and LMP7 would thus enhance cell survival and proliferation,
this way resulting in a poorer clinical outcome.
Notably, a high expression of LMP2 and LMP7 is not always
associated with an increased antigen presentation. Thus, in a study on
Epstein-Barr virus-transformed B cells as well as in other cell types, the
presence of the immunoproteasome instead of the standard proteasome
inhibited the presentation of specific peptides [42]. In addition, in a report
byMehta et al., it was noted that down-regulation of LMP2 andLMP7was
associated with an absence of lymph node metastasis, possibly due to a
similar mechanism [26]. It is possible that the results obtained in the
present study, at least partially, may be caused by a decreased recognition
of specific peptides, e.g., HPV-derived peptides, by immune cells due to a
difference in peptides produced by the immunoproteasome compared to
those produced by the standard proteasome.
It is important to note that the expression of APM components was
here analyzed in pretreatment tumors, in a situation where the tumor
is still growing and the immune defence has so far failed to reject the
tumor. We do not know whether expression of these components is
affected by treatment and whether the immune defence plays a role
during successful, relapse-free, treatments. The results in the present
study indicate that LMP7, and possibly also LMP2, can potentially be
useful together with other biomarkers, including HPV status, for
predicting clinical outcome [13,16,27,43].There are some limitations in the present study. Although 151
tumors were included, when separated for HPV-positive and HPV-
negative status and analyzed for correlations between different APM
components, random correlations may still be obtained. For this
reason, only the stronger associations, found for both HPV-positive
and HPV-negative tumors, were noted, although some weaker
correlations may also be valid. Furthermore, not all APM components
were evaluated. An analysis of the expression of additional
components, e.g., β2-microglobulin, calnexin, tapasin, and ERp57,
may have contributed by giving a fuller view of the combined
expression of different APM components in these tumors. For
the staining of TAP1, TAP2, LMP2, and LMP7, we have used
commercially available antibodies and we have trusted the manufac-
turers’ descriptions of their specificity. However, we cannot fully
exclude the possibility of cross-reactions with other proteins that we
are not aware of.
In conclusion, TAP2, LMP2, and LPM7 expression was, similar to
HLA class I and LMP10, frequently absent or reduced in many TSCC
and BOTSCC, and correlations between the analyzed APM components
were noted. In addition, for HPV-positive tumors, LMP2, LMP7, and
HLA class I expression were correlated. For HPV-positive TSCC and
BOTSCC, absent/low nuclear LMP7 expression was correlated to better
clinical outcome in linewith earlier data on absent/lowHLA class I and/or
nuclear LMP10 expression [15,16,27].
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